A Single-Center, Single-Dose, Randomized, Open-Label, Single-Period, Parallel Bioequivalence Study of BGM0504 Injection in Overweight/Obese Participants
Latest Information Update: 09 Feb 2026
At a glance
- Drugs BGM 0504 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors BrightGene Bio-medical technology
Most Recent Events
- 09 Feb 2026 New trial record